Two standard hospital pumps have been modified to provide bimodal insulin delivery for use as "open loop+ artificial beta cells. The units have been designed to deliver both a low infusion basal rate of insulin for glycemic control during a fasting state in diabetics and a high infusion rate in response to a meal challenge. The basal rate can be varied in steps of 0;2 milliliter per hour from roughly one to three milliliters per hour. The higher infusion rate can be 10 to 20 times the basal rate in steps of two milliliter per hour with an automatic return to the basal rate after a 1- to 99-minute programmable interval. The burst rate is initiated manually at the start of a meal. Displays and monitors are available to indicate the basal and high delivery rates and times. The units have been used for intravenous and intraperitoneal insulin delivery in animals and diabetic patients. There is an improvement in glycemic control and normalization of plasma-free insulin levels in juvenile-onset diabetics treated with this pulsed mode of insulin delivery. The variation in pumping rates provides flexibility in treatment of a variety of glycemic challenges.

Download full-text PDF

Source

Publication Analysis

Top Keywords

insulin delivery
16
basal rate
16
hospital pumps
8
glycemic control
8
infusion rate
8
steps milliliter
8
milliliter hour
8
rate
7
insulin
6
delivery
5

Similar Publications

How Health Systems World-wide Fail Type 2 Diabetics.

Health Syst Reform

December 2025

Independent Consultant, Alexandria, VA, USA.

For over 50 years, health systems the world over have failed people with type 2 diabetes mellitus (T2DM). The WHO documents a quadrupling of people with diabetes in a 34-year period to 422 million in 2014, the overwhelming majority of whom were T2DM. This happened despite extensive scientific literature on the causes of, as well as proven treatments for, this disease.

View Article and Find Full Text PDF

Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers.

Diabetologia

January 2025

Department of Chemical and Biological Engineering, Colorado School of Mines, Golden, CO, USA.

Type 1 diabetes is an autoimmune disease characterised by the destruction of pancreatic beta cells, resulting in lifelong insulin dependence. Although exogenous insulin can maintain glycaemic control, this approach does not protect residual or replacement pancreatic beta cells from immune-mediated death. Current therapeutics designed to protect functional beta cell mass or promote beta cell proliferation and regeneration can have off-target effects, resulting in higher dose requirements and adverse side effects.

View Article and Find Full Text PDF

Diabetes mellitus, characterized by high blood glucose due to inadequate insulin action, comprises two main types: type 1, an autoimmune disease, and type 2, marked by insulin resistance. This review provides a comprehensive overview of diabetes management and treatment advancements. Effective diabetes management includes maintaining blood glucose levels within normal ranges and monitoring HbA1c, a marker reflecting average glucose levels over the past few months.

View Article and Find Full Text PDF

Diabetes is a metabolic disorder caused by the body's inability to produce or use insulin. Considering the figures projected by the World Health Organization, research on insulin therapy is crucial. Hence, we present a soft biointerface based on a thiol-yne poly(ethylene glycol) (PEG) click-hydrogel as an advanced treatment option to administrate insulin.

View Article and Find Full Text PDF

Objective: To evaluate the safety and efficacy of the Medtronic 780G SmartGuard™ AID system in children under 7 years of age with type 1 diabetes (T1D).

Methods: Retrospective analysis of data from children living with T1D under 7 years of age using the MiniMed 780G™ across three pediatric endocrinology units in the Canary Islands. Metabolic control parameters were analyzed from 14 days of pretreatment to 12 months of follow-up.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!